Product Images Topiramate

This is a chart comparing the cumulative rates for time to first seizure between two groups of patients taking different doses of topiramate (50mg/day and 400mg/day). The chart shows the time in days on the x-axis and the cumulative rates on the y-axis. The chart also indicates that the results have a statistical significance (P=0.0002).*

The text describes the change in average monthly migraine period rate during a double-blind phase in a study involving the drug topiramate compared to a placebo. The study tested varying doses of topiramate (50mg/day, 100mg/day, and 200mg/day) compared to a placebo, and involved a total of 1152 participants (split into smaller groups). The table presents the results in terms of the number of participants in each group and the statistical significance of the differences between groups, denoted by p-values.*

This is a description of Topiramate medication, containing 30 HD3 tablets, and should be taken only with a doctor's prescription. It provides information about the NDC number and the source NDC. It was manufactured by Zydus Pharm, Pennington, N.J 08534. The medication should be stored at 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F). The package insert provides instructions for use. Also, it was repackaged by RemedyRepack Inc., Indiana, PA 15701.*

Topiramate is a prescription medication available in a pack of 90 HD3 tablets. The medicine is manufactured by Zydus Pharm in Pennington, N.J 08534. The NDC number is 70518-1953-01 and the source NDC is 68382-0140-05. The medicine should be kept out of the reach of children and stored at 20-26°C (63-77°F). In case of excursions, the temperature can be permitted to 15-30°C (59-86°F) in accordance with the USP. The package insert should be consulted for directions for use. The medicine has been repackaged by RemedyRepack Inc., Indiana, PA 15701.*